The Human Gut Microbiome: Mechanistic Insights into Obesity, Diabetes and Systemic Autoimmunity

Abstract

The human microbiome, a complex of microorganisms outnumbering human cells by approximately ten to one, serves as a critical regulator of systemic health. This paper investigates the intricate relationship between microbial dysbiosis and the pathogenesis of obesity, type 2 diabetes (T2DM), and autoimmune disorders. By synthesizing recent metagenomic data and clinical findings, this review explores how the loss of microbial diversity and alterations in the Firmicutes/Bacteroidetes ratio contribute to increased energy harvest and metabolic inflammation. Key results highlight the role of short-chain fatty acids (SCFAs), such as butyrate and propionate, in modulating insulin sensitivity and appetite regulation. Furthermore, the review examines how the 'leaky gut' phenomenon allows lipopolysaccharides (LPS) to trigger chronic systemic inflammation, driving both insulin resistance and autoimmune responses. Specific attention is given to therapeutic interventions; findings indicate that Fecal Microbiota Transplantation (FMT) can achieve up to 100% donor engraftment when combined with lifestyle changes, significantly improving glycemic markers. The study concludes that while animal models provide foundational insights, large-scale clinical trials are essential to transition toward personalized, microbiome-targeted therapies in precision medicine.